Chromosome 10q26-driven age-related macular degeneration is associated with reduced levels of <i>HTRA1</i> in human retinal pigment epithelium.

Abstract

Genome-wide association studies have identified the chromosome 10q26 (Chr10) locus, which contains the age-related maculopathy susceptibility 2 (<i>ARMS2</i>) and high temperature requirement A serine peptidase 1 (<i>HTRA1</i>) genes, as the strongest genetic risk factor for age-related macular degeneration (AMD) [L.G. Fritsche et al., <i>Annu. Rev. Genomics Hum. Genet.</i> 15, 151-171, (2014)]. To date, it has been difficult to assign causality to any specific single nucleotide polymorphism (SNP), haplotype, or gene within this region because of high linkage disequilibrium among the disease-associated variants [J. Jakobsdottir et al. <i>Am. J. Hum. Genet.</i> 77, 389-407 (2005); A. Rivera et al. <i>Hum. Mol. Genet.</i> 14, 3227-3236 (2005)]. Here, we show that <i>HTRA1</i> messenger RNA (mRNA) is reduced in retinal pigment epithelium (RPE) but not in neural retina or choroid tissues derived from human donors with homozygous risk at the 10q26 locus. This tissue-specific decrease is mediated by the presence of a noncoding, cis-regulatory element overlapping the <i>ARMS2</i> intron, which contains a potential Lhx2 transcription factor binding site that is disrupted by risk variant rs36212733. HtrA1 protein increases with age in the RPE-Bruch's membrane (BM) interface in Chr10 nonrisk donors but fails to increase in donors with homozygous risk at the 10q26 locus. We propose that HtrA1, an extracellular chaperone and serine protease, functions to maintain the optimal integrity of the RPE-BM interface during the aging process and that reduced expression of <i>HTRA1</i> mRNA and protein in Chr10 risk donors impairs this protective function, leading to increased risk of AMD pathogenesis. HtrA1 augmentation, not inhibition, in high-risk patients should be considered as a potential therapy for AMD.